The purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with CD30-positive cancers and to determine the main route of excretion. The study will also assess blood drug levels in patients with renal or hepatic impairment (special populations).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
73
City of Hope
Duarte, California, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
St. Francis Medical Group Oncology & Hematology Specialists
Indianapolis, Indiana, United States
Karmanos Cancer Institute / Wayne State University
Detroit, Michigan, United States
Midazolam blood concentrations +/- brentuximab vedotin
Time frame: 3 weeks
Brentuximab vedotin blood concentrations +/- rifampin
Time frame: 6 weeks
Brentuximab vedotin in urine, feces, and blood
Time frame: 1 week
Brentuximab vedotin blood concentrations in special populations
Time frame: 3 weeks
Brentuximab vedotin blood concentrations +/- ketoconazole
Time frame: 6 weeks
Incidence of adverse events and laboratory abnormalities
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
400 mg/day PO
1.2 mg/kg IV every 21 days
Hackensack University Medical Center
Hackensack, New Jersey, United States
Seattle Cancer Care Alliance / University of Washington Medical Center
Seattle, Washington, United States